Columbus CyberKnife is proud to commemorate the 20th anniversary of CyberKnife® technology in 2014. Developed in 1994 at Stanford by Dr. John Adler, the concept was conceived with the goal of treating tumors throughout the body with radiosurgery, a treatment that at the time was restricted to head and neck tumors.
Key CyberKnife milestones:
- The prototype system developed by Dr. Adler was used from 1994 to 2001 at Stanford.
- The U.S. Food and Drug Administration approved the CyberKnife for treatment of tumors in the head and neck in 1999.
- In 2001, the FDA approved the technology for the treatment of tumors throughout the body.
Over the last 20 years, CyberKnife has been adopted internationally for the treatment of primary and metastatic tumors, including those in the lungs, brain, spine, liver, kidney and prostate.
CyberKnife manufacturer, Accuray, reports that the system has been used in 40 countries to treat more than half a million patients to date. Over the last two decades, CyberKnife has evolved as a treatment method with expanded applications for different diseases. The growth and availability of long-term clinical research results has further demonstrated the treatment’s efficacy and has led to the publication of updated treatment guidelines and policies from a host of health care organizations.
To learn more about Columbus CyberKnife and the conditions we treat, contact us.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.